U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including: http://www.umces.edu/sites/default/files/pdfs/oraa/guidance_for_industry.pdf https://www.acs.org/content/acs/en/molecule-of-the-week/archive/i/isoeugenol.html

Clove oil is a natural product, derived from the Eugenia caryophyllata tree. Clove oil is 85 to 95% eugenol. Isoeugenol and methyleugenol make up 5 to 15% of the remaining ingredients. Isoeugenol is manufactured from eugenol by a process of isomerization. Isoeugenol have been used in foods and eugenol has been used in animal feeds. Isoeugenol is used as a fish anesthetic. The mechanism of action of isoeugenol in fish has not been determined. It is hypothesised that its effects are mediated via receptors controlling cellular ion channels in a similar way to that described for local anaesthetics. Reports of adverse reactions involving the use of isoeugenol in humans are primarily confined to incidents of contact sensitization or allergy following dermal exposure.

Originator

Sources: Riechstoff ind. Volume 7, Pages 112, Journal, 1932DOI: 10.1002/cber.189102402113

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
TRUE Test

Approved Use

Unknown
Diagnostic
TRUE Test

Approved Use

Fragrance mix is composed of eight substances, including isoeugenol (approximately 15 ug).
Doses

Doses

DosePopulationAdverse events​
2 % single, topical
Highest studied dose
Dose: 2 %
Route: topical
Route: single
Dose: 2 %
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Other AEs: Allergic contact dermatitis...
Other AEs:
Allergic contact dermatitis (95%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Allergic contact dermatitis 95%
2 % single, topical
Highest studied dose
Dose: 2 %
Route: topical
Route: single
Dose: 2 %
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Chemical allergens stimulate human epidermal keratinocytes to produce lymphangiogenic vascular endothelial growth factor.
2015-03-01
In vitro activity of natural phenolic compounds against fluconazole-resistant Candida species: a quantitative structure-activity relationship analysis.
2014-04
Development of a new in vitro skin sensitization assay (Epidermal Sensitization Assay; EpiSensA) using reconstructed human epidermis.
2013-12
Antifungal efficacy of some natural phenolic compounds against significant pathogenic and toxinogenic filamentous fungi.
2013-10
NCTC 2544 and IL-18 production: a tool for the identification of contact allergens.
2013-04
Development of an in vitro dendritic cell-based test for skin sensitizer identification.
2013-03-18
Differentiation of skin sensitizers from irritant chemicals by interleukin-1α and macrophage inflammatory protein-2 in murine keratinocytes.
2013-01-10
B cell increases and ex vivo IL-2 production as secondary endpoints for the detection of sensitizers in non-radioisotopic local lymph node assay using flow cytometry.
2012-03-25
Isoeugenol destabilizes IL-8 mRNA expression in THP-1 cells through induction of the negative regulator of mRNA stability tristetraprolin.
2012-02
Impact of eugenol and isoeugenol on AhR translocation, target gene expression, and proliferation in human HaCaT keratinocytes.
2012
An in vitro test to screen skin sensitizers using a stable THP-1-derived IL-8 reporter cell line, THP-G8.
2011-12
Active transport of contact allergens in human monocyte-derived dendritic cells is mediated by multidrug resistance related proteins.
2011-04-15
The intra- and inter-laboratory reproducibility and predictivity of the KeratinoSens assay to predict skin sensitizers in vitro: results of a ring-study in five laboratories.
2011-04
The mouse eugenol odorant receptor: structural and functional plasticity of a broadly tuned odorant binding pocket.
2011-02-08
Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds.
2010-09
A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells.
2010-09
Identification of PDL-1 as a novel biomarker of sensitizer exposure in dendritic-like cells.
2010-09
Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by down-regulation of NF-kappaB, ERK1/2, and p38 kinase.
2007-12-08
Chemicals with weak skin sensitizing properties can be identified using low-density microarrays on immature dendritic cells.
2007-11-01
Suppression of interleukin-2 gene expression by isoeugenol is mediated through down-regulation of NF-AT and NF-kappaB.
2007-09
Do anesthetics and sampling strategies affect transcription analysis of fish tissues?
2007-06-08
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006-11
Impact of the arylhydrocarbon receptor on eugenol- and isoeugenol-induced cell cycle arrest in human immortalized keratinocytes (HaCaT).
2006-09
An odorant derivative as an antagonist for an olfactory receptor.
2004-11
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.
2003-10
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens.
2001-03
Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis.
2000-06-08
Liquid chromatographic separation and fluorometric determination of cis- and trans-isoeugenol in perfumes, colognes, and toilet waters.
1988-07-01
Patents

Sample Use Guides

Subjects were investigated by closed patch test using 8mm Finn Chambers1 on Scanpor1 tape (Epitest, Tuusula, Finland) dosed with (E)-Isoeugenol (1.0% pet.) Chambers were removed after 2 days. Reactions were read on 2 occasions over 5 days.
Route of Administration: Topical
Isoeugenol in low concentrations 206 uM caused a distinct decrease in twitch response in phrenic nerve-diaphragm preparations.
Substance Class Mixture
Created
by admin
on Mon Mar 31 18:49:51 GMT 2025
Edited
by admin
on Mon Mar 31 18:49:51 GMT 2025
Record UNII
5M0MWY797U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOEUGENOL
FCC   FHFI   INCI   MI  
INCI  
Official Name English
NSC-6769
Preferred Name English
ISOEUGENOL [FHFI]
Common Name English
4-HYDROXY-3-METHOXY-1-PROPENYLBENZENE
Common Name English
2-METHOXY-4-(1-PROPENYL)PHENOL
Common Name English
2-METHOXY-4-PROPENYLPHENOL
Common Name English
ISOEUGENOL [FCC]
Common Name English
FEMA NO. 2468
Code English
ISOEUGENOL [USP-RS]
Common Name English
ISOEUGENOL [MI]
Common Name English
4-PROPENYLGUAIACOL
Common Name English
Classification Tree Code System Code
WHO-VATC QN01AX94
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
JECFA EVALUATION ISOEUGENOL
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
CFR 21 CFR 172.515
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
EC SCIENTIFIC COMMITTEE ON CONSUMER SAFETY OPINION SCCS/1459/11
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
NDF-RT N0000185508
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID7022413
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
NDF-RT
N0000175629
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY Increased Histamine Release [PE]
RS_ITEM_NUM
1348532
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
CAS
97-54-1
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
202-590-7
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
HSDB
8044
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
DAILYMED
5M0MWY797U
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
MESH
C036643
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
WIKIPEDIA
ISOEUGENOL
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
NDF-RT
N0000171131
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY Allergens [Chemical/Ingredient]
SMS_ID
100000134261
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
RXCUI
1363706
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY RxNorm
CHEBI
18224
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
NDF-RT
N0000184306
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY Cell-mediated Immunity [PE]
DRUG BANK
DB14188
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
CHEBI
50545
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
FDA UNII
5M0MWY797U
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
MERCK INDEX
m6486
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY Merck Index
NSC
6769
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
EVMPD
SUB61020
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
JECFA MONOGRAPH
1269
Created by admin on Mon Mar 31 18:49:51 GMT 2025 , Edited by admin on Mon Mar 31 18:49:51 GMT 2025
PRIMARY
Any of these components may be present:
Related Record Type Details
ACTIVE MOIETY
Definition References